# Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

> **NCT01986907** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1049 (actual)

## Conditions studied

- Wet Age Related Macular Degeneration

## Interventions

- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT01986907
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-04
- **Primary completion:** 2016-06-15
- **Final completion:** 2016-06-15
- **Target enrollment:** 1049 (ACTUAL)
- **Last updated:** 2019-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986907, "Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01986907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*